Celanese to sell oxo business to Advent for $630M

Celanese Corporation on December 13 announced that it has entered into an agreement to sell its oxo products and derivatives businesses, including European Oxo GmbH (EOXO), a joint venture between Celanese AG and Degussa AG, to Advent International, a global private equity firm, for the purchase price of EUR €480 million, which is approximately USD $630 million at current exchange rates. This sale is consistent with Celanese’s strategy to optimize its portfolio and divest non-core businesses.  

“Celanese is committed to a hybrid business model with leading global businesses that are integrated and focused around core strengths,” said David Weidman, president and chief executive officer. “This sale allows us to continue our strategic execution to focus our portfolio and position Celanese for strong, sustainable earnings growth and increased value.”   

The sale includes oxo and derivative businesses at Celanese’s Oberhausen, Germany, and Bay City, Texas, facilities; and portions of its Bishop, Texas, facility. EOXO’s facilities within the Oberhausen and Marl, Germany, plants are also included in the sale. As part of the transaction, Celanese will transfer all of the EOXO business to Advent International, including Degussa’s 50 percent interest of the venture.

“We are confident that customer supply will not be disrupted as we transition through this process,” Weidman said. “In addition, we believe that this sale will allow Advent International to focus and further strengthen these businesses in a manner consistent with customer interests.”

“Leveraging Advent’s industry sector knowledge, we will work with this acquired business’ management team to integrate its activities and accelerate growth,” said Ronald Ayles, Advent International.

The oxo derivative chemicals business of Celanese, which has approximately 1,100 employees, earns revenues of approximately $700 million and has EBITDA margins of about 10 percent. EOXO, which has approximately 200 employees, has non-consolidated revenues of approximately $700 million and contributes $5 million to $10 million of equity earnings to Celanese annually. The transaction is subject to customary closing conditions, including consent from senior secured lenders and regulatory approvals.